logo-loader
viewOpen Orphan PLC

Open Orphan: Leveraging expertise and relationships for growth

Open Orphan (ORPH) is targeting rapid scale-up and profitability in the dynamic European orphan and rare disease consulting sector via acquisitions and organic means. The sector is reported to be growing at circa 11%, double the growth rate of the broader pharma market. The company’s Venn Life Sciences consulting arm, which counts an array of leading biopharma companies among its customers, is advancing its strategy of signing up long term partnerships with industry clients, providing substantial revenue prospects. In parallel, the company is close to launching its pioneering European rare disease, advocacy-led Genomic Health DataBANK platform and has signed five biopharma early adopters to trial its analytical capabilities.

 

Quick facts: Open Orphan PLC

Price: 5.925 GBX

AIM:ORPH
Market: AIM
Market Cap: £32.53 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Open Orphan catching global attention with 'stunning' FLU-v results &...

Open Orphan PLC's (LON:ORPH) Cathal Friel and its subsidiary hVIVO's chief scientist Dr Andrew Catchpole sat down with Proactive London's Andrew Scott. This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they're jointly developing have been...

3 weeks, 2 days ago

4 min read